By Chen Ke

  Recently, a famous domestic biopharmaceutical company which is building a production base in Nantong Economic & Technological Development Area, Biotheus Inc. has reached an equity acquisition agreement with BioNTech, a global pharmaceutical giant from Germany. 

  According to the agreement, BioNTech will acquire 100% of Biotheus' issued share capital with an advance payment of $800 million. The deal is expected to be completed in the first quarter of 2025. 

  Biotheus (Nantong) Co., Ltd., as an important part in the building of a complete industrial chain for antibody new drug development of Biotheus Inc., has a 61,000 square meters industrialized production base that meets international standards in Nantong Economic & Technological Development Area, which takes on the responsibility of the group’s industrial production. After the completion of this equity acquisition, Biotheus (Nantong) will continue to take root in Nantong Economic & Technological Development Area, and build a first-class biopharmaceutical production base. At the same time, Biotheus (Nantong) will function as the only industrial production base of BioNTech in China at present, to make contributions to its global products’ production and supply. 

  BioNTech is a Fortune Global 500 company which is leading in mRNA vaccine research and development in the world. It is dedicated to developing a new generation of immunotherapies for cancer and other major diseases.

【背景阅读】

南通一药企与德国BioNTech达成合作

    近日，在南通开发区建设生产基地的国内知名生物医药企业普米斯生物技术公司与全球药企巨头德国BioNTech（百欧恩泰）达成股权收购协议。

    根据协议条款，BioNTech将以8亿美元预付款收购普米斯100%已发行股本。此外，BioNTech将在普米斯达到双方约定的里程碑条件时，额外支付最高1.5亿美元的里程碑付款。该交易预计于2025年第一季度完成。

    普米斯南通公司作为普米斯集团构建抗体新药开发完整产业链中的重要一环，在南通开发区建有6.1万平方米的符合国际标准的产业化生产基地，承担集团的产业化生产重任。本次股权收购完成后，普米斯南通公司将继续扎根开发区，打造一流的生物医药生产基地。同时，普米斯南通公司将作为BioNTech目前在国内唯一的产业化生产基地，为其全球产品生产和供应作出贡献。

    BioNTech公司是一家全球领先的从事mRNA疫苗研发的世界500强企业，致力于开创癌症及其他重大疾病的新一代免疫疗法。  

作者：陈可